香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不就因本通告全部或任何部份內容而產生或因依賴該等內容而引致的任 何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （股份代號：2315） 2026年第一次臨時股東會通告 茲通告百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）謹定於2026年2月12 日（星期四）下午二時正（香港時間）假座中國北京市大興區大興生物醫藥產業基地寶參 南街12號院會議室以現場會議結合網上虛擬會議的方式舉行2026年第一次臨時股東會 （「臨時股東會」），以考慮及酌情批准下列決議案。除另有界定外，本通告所用詞彙與 本公司日期為2026年1月27日的通函（「通函」）所界定者具有相同涵義。 普通決議案 1. 審議及批准建議委任劉弘康先生為本公司非執行董事。 上述建議於臨時股東會上提呈的決議案詳情載於通函，通函可於香港聯交所網站 ( www.hkexnews.hk )及本公司網站( www.biocytogen.co ...

智通财经APP讯，百奥赛图-B(02315)发布公告，经董事会提名委员会提名及董事会审议，董事会于2026 年1月27日举行的董事会会议上建议委任刘弘康先生为非执行董事。 ...

百奥赛图-B(02315)发布公告，经董事会提名委员会提名及董事会审议，董事会于2026年1月27日举行的 董事会会议上建议委任刘弘康先生为非执行董事。 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取之行動有任何疑問，應諮詢 閣下之股票經紀或其他持牌證券交易商、 銀行經理、律師、專業會計師或其他專業顧問。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 建議委任非執行董事； 及 2026年第一次臨時股東會通告 董事會函件載於本通函第3至6頁。 本公司將於2026年2月12日（星期四）下午二時正召開臨時股東會，會議將由假座中國北京市大興區大興生 物醫藥產業基地寶參南街12號院會議室舉行的現場會議結合網上虛擬會議的方式舉行，有關大會或其任何 續會或延會之通告載於本通函第N-I-1至N-I-2頁。 適用於臨時股東會之H股股東代表委任表格可於本公司網站( https://www.biocytogen.com.cn )及香港交易及 結算所有限公司網站( www.hkexnews.hk )下載。本公司建議H股股東應盡快，但無論如何不遲於臨時股東 會或其任何續會（視情況而定）指定舉行時間前24小時（即不遲於2026年2月 ...

百奧賽圖（北京）醫藥科技股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 建議委任非執行董事 百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 欣然宣布，經董事會提名委員會提名及董事會審議，董事會於2026年1月27日舉 行的董事會會議上建議委任劉弘康先生（「劉先生」）為非執行董事。 有關劉先生的履歷詳情載列如下： 劉弘康先生，35歲，自2021年6月起加入國投創業投資管理有限公司，目前擔任 該公司投資經理。劉先生分別於2012年及2020年獲得中國華中科技大學生物技術 學士學位及生物物理學博士學位。 於本公告日期，除上文所披露者外，劉先生確認(i)彼並無於本公司或本公司任何 其他成員公司擔任任何職位；(ii)彼於過往三年內並無在其證券於香港或海 ...

证券日报网讯 1月27日，百奥赛图发布公告称，同意提名刘弘康先生为公司第二届董事会非执行董事候 选人。 ...

（股份代號：2315） 暫停辦理H股過戶登記手續 百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）董事（「董事」）會（「董事會」） 謹此宣佈，本公司將於2026年2月12日（星期四）下午二時正假座中國北京市大興 區大興生物醫藥產業基地寶參南街12號院會議室以現場會議結合網上虛擬會議的 方式舉行本公司臨時股東大會（「臨時股東大會」）。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 百奧賽圖（北京）醫藥科技股份有限公司 董事長、首席執行官兼執行董事 沈月雷 香港，2026年1月26日 於本公告日期，董事會包括董事長、首席執行官兼執行董事沈月雷博士、執行董 事倪健博士；非執行董事周可祥博士及張蕾娣女士；獨立非執行董事華風茂先 生、喻長遠博士及梁曉燕女士；及職工董事李妍女士。 為釐 ...

Core Insights - The report highlights the significant presence of public funds in the stock market, with 2,977 stocks appearing in fund heavy positions as of the end of Q4 last year, indicating a clear trend in institutional investment strategies [1] - A total of 107 stocks have a fund holding ratio exceeding 10%, showcasing the high influence and control of institutional funds over these stocks [1] Group 1: Fund Holdings and Stock Performance - Among the 107 stocks with over 10% fund holdings, 56 saw increased investments in Q4, with notable increases in holdings for ShenGong Co., Tianhua New Energy, and Maiwei Co., with increases of 59,020.96%, 15,808.35%, and 959.13% respectively, indicating strong institutional confidence in their fundamentals [2] - Conversely, 48 stocks experienced reductions in fund holdings, with notable decreases for Nuocheng Jianhua-U, Kaiter Co., and Keda Li, with reductions of 43.91%, 41.04%, and 39.95% respectively [2] - Three new stocks entered the heavy holding category, with Baiao Saitu, Litong Technology, and Xingtou Measurement Control having fund holding ratios of 21.55%, 12.60%, and 10.03% respectively [2] Group 2: Institutional Investment Trends - The phenomenon of institutional clustering remains significant, with over 100 funds holding 42 of the 107 stocks, and 29 stocks held by 50 to 99 funds, indicating a strong consensus among institutional investors [4] - Notably, Ningde Times, despite a holding ratio of 11.63%, has the highest number of fund holders at 2,056, followed by Zhongji Xuchuang, Zijin Mining, and Xinyi with over 1,300 fund holders each [4] - The stocks with high fund holdings are predominantly in the "hard technology" and "innovation" sectors, with 42 from the Sci-Tech Innovation Board, 27 from the Growth Enterprise Market, and 31 from the Shanghai and Shenzhen main boards, reflecting a focus on growth sectors [4] Group 3: Performance Expectations - Among the 107 stocks, 26 have released performance forecasts for 2025, with 18 expecting profit increases, 4 expecting declines, and 2 forecasting losses, indicating a generally positive outlook [5] - The highest expected profit growth is for Baiwei Storage at 473.71%, followed by Changxin Bochuang and Baiao Saitu with expected growths of 378.70% and 303.57% respectively, providing strong support for long-term fund holdings [5] - The concentration of fund holdings in the electronics and biopharmaceutical sectors suggests an increased market expectation for technological innovation and consumer recovery [5]

Core Viewpoint - Company is rated "Buy" by Guotai Junan Securities, highlighting its position as a leading global preclinical CRO and biotechnology firm with strong technical barriers and stable revenue growth from preclinical products and services [1] Group 1: Revenue Growth and Business Model - Preclinical products and services are the foundation of the company's business, with revenue growing rapidly due to leading gene editing technologies and a high-quality humanized antibody mouse platform [2] - Sales of model animals increased from 66 million yuan in 2021 to 389 million yuan in 2024, with a CAGR exceeding 50% [2] - The company has established long-term partnerships with over 950 global partners, completing more than 6,350 drug evaluation projects, maintaining a clinical preclinical pharmacology customer retention rate above 60% [2] Group 2: Antibody Development and Growth Engines - The "Thousand Mice and Ten Thousand Antibodies" plan is entering a monetization phase, with antibody development and licensing becoming strong growth drivers [2] - Revenue from antibody development increased from 127 million yuan in 2022 to 318 million yuan in 2024, with a CAGR of 58% and a gross margin exceeding 90% in 2024 [2] - The million-level antibody sequence library provides high-quality antibody molecules for global partners and maximizes technical value through various models such as licensing and collaborative development [2]

Core Viewpoint - Company is rated "Buy" by Guotai Junan Securities, highlighting its position as a leading global preclinical CRO and biotechnology firm with strong technical barriers and stable revenue growth from preclinical products and services [1] Group 1: Revenue Growth and Business Model - Preclinical products and services are the foundation of the company's business, with revenue growing rapidly; model animal sales are projected to increase from 66 million yuan in 2021 to 389 million yuan in 2024, with a CAGR exceeding 50% [1] - The company has established long-term partnerships with over 950 global collaborators, including the top ten pharmaceutical companies, completing over 6,350 drug evaluation projects [1] - The company has a strong overseas presence, with higher average order values from international clients compared to domestic ones, enhancing its risk resistance and profitability [1] Group 2: Antibody Development and Growth Engine - The "Thousand Mice and Ten Thousand Antibodies" plan is entering a realization phase, with antibody development and licensing becoming a significant growth driver; revenue from antibody development is expected to grow from 127 million yuan in 2022 to 318 million yuan in 2024, with a CAGR of 58% [2] - The company’s innovative "antibody shelf" model breaks traditional efficiency bottlenecks in antibody development, providing high-quality antibody molecules for global partners and maximizing technical value through various collaboration models [2] - The core pipeline focuses on high-value areas, complementing collaborative pipelines and gradually realizing commercial potential, thus creating a new growth engine [2] Group 3: Catalysts - Sales of model animals are expected to exceed forecasts, and the antibody licensing business is anticipated to realize results beyond expectations [3]